Similarly, several promising therapeutic targets have been identified using the NPcis MPNST mouse model, including epidermal growth factor receptory (EGFR) and mechanistic target of rapamycin (mTOR), but none have demonstrated activity in clinical trials for MPNST [14,93,94]. The gene discussed is EGFR; the disease is malignant peripheral nerve sheath tumor.